HRP20160465T1 - Novi supstituirani derivati izokinolina - Google Patents
Novi supstituirani derivati izokinolina Download PDFInfo
- Publication number
- HRP20160465T1 HRP20160465T1 HRP20160465TT HRP20160465T HRP20160465T1 HR P20160465 T1 HRP20160465 T1 HR P20160465T1 HR P20160465T T HRP20160465T T HR P20160465TT HR P20160465 T HRP20160465 T HR P20160465T HR P20160465 T1 HRP20160465 T1 HR P20160465T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- groups
- alkyl
- amino
- alkynyl
- Prior art date
Links
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000002252 acyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 150000004280 isoquinoline-6-sulfonamides Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Claims (10)
1. Izokinolin-6-sulfonamid derivat predstavljen Formulom (1), sol istog ili solvat derivata ili sol:
[image]
naznačen time, da
R1 i R2 svaki neovisno predstavlja atom vodika, atom halogena, cijano skupinu, alkilnu skupinu, halogenoalkilnu skupinu, alkenilnu skupinu, alkinilnu skupinu, alkoksi skupinu, alkiltio skupinu, hidroksilnu skupinu, merkapto skupinu, nitro skupinu, amino skupinu, aminoalkiltio skupinu ili heteroarilnu skupinu;
R3 i R4 svaki neovisno predstavlja atom vodika, alkilnu skupinu, hidroksialkilnu skupinu, dialkilaminoalkilnu skupinu ili aminoalkanoilnu skupinu;
R5 predstavlja atom vodika, po izboru supstituiranu alkilnu skupinu, alkenilnu skupinu, po izboru supstituiranu alkinilnu skupinu, po izboru supstituiranu cikloalkilnu skupinu ili po izboru supstituiranu alkanoilnu skupinu ili R4 i R5 mogu tvoriti zasićeni heterociklički prsten zajedno sa susjednim atomom dušika, pri čemu je supstituent na alkilnoj skupini, alkinilna skupina, cikloalkilna skupina oili alkanoilna skupina u R5 je najmanje jedn supstituient odabran od (a) cikloalkilne skupine, arilne skupine, heteroarilne skupine, ariloksi skupine, heteroariloksi skupine, arilenske skupine ili heteroarilenske skupine koja po izboru ima, na prstenu, najmanje jedn supstituent odabran od atoma halogena, cijano skupine, alkilne skupine, halogenoalkilne skupine, alkenilne skupine, alkinilne skupine, alkoksi skupine, alkiltio skupine, hidroksilne skupine, okso skupine, skupine formula, alkanoilne skupine, karboksilne skupine, alkiloksikarbonilne skupine, merkapto skupine, nitro skupine, amino skupine, urea skupine, tiourea skupine i aminoalkilne skupine, (b) hidroksilne skupine, (c) okso skupine, (d) alkanoiloksi skupine, (e) amino skupine, (f) karboksilne skupine, (g) alkoksi skupine i (h) alkilooksikarbonilne skupine; i A predstavlja ravnu ili razgrananu alkilensku skupinu koja ima 2 do 6 ugljikovih atoma i po izboru ima najmanje jedan supstituent odabran od karboksilne skupine, atoma halogena, cijano skupine, okso skupine, alkenilne skupine, alkinilne skupine, alkoksi skupine, hidroksilne skupine, alkiloksikarbonilne skupine, aminoalkilne skupine, arilne skupine, heteroarilne skupine, po izboru supstituiranu aralkilnu skupinu i po izboru supstituiranu heteroarilakilnu skupinu, pri čemu aralkilna skupina ili heteroarilalkilna skupina u A po ziboru imaju najmanje jedan supstituent odabran od atoma halogena, cijano skupine, alkilne skupine, halogenoalkilne skupine, alkenilne skupine, alkinilne skupine, alkoksi skupine, alkiltio skupine, hidroksilne skupine, okso skupine, skupine formila, alkanoilne skupine, karboksilne skupine, alkiloksikarbonilne skupine, merkapto skupine, nitro skupine, amino skupine, urea skupine, tiourea skupine i aminoalkilne skupine.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da R1 i R2 su svaki neovisno atom vodika, atom halogena, C1-8 alkilna skupina, nitro skupina, cijano skupina, halogeno C1-8 alkilna skupina, fenilna skupina, C2-8 alkenilna skupina, C2-8 alkinilna skupina, hidroksilna skupina, amino skupina, amino C1-8 alkiltio skupina ili tienil skupina.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time, da je supstituent na alkilnoj skupini, alkinilnoj skupini, cikloalkilnoj skupini ili alkanoilnoj skupini u R5 najmanje jedan supstituent odabran od (a) arilne skupine, heteroarilne skupine ili arilenske skupine koji po izboru ima, na prstenu, najmanje jedan supstituent odabran od atoma halogena, cijano skupine, C1-8 alkilne skupine, halogeno C1-8 alkilne skupine, C2-8 alkenilne skupine, C2-8 alkinilne skupine, C1-8 alkoksi skupine, C1-8 alkiltio skupine, hidroksilne skupine, okso skupine, skupine formila, C1-8 alkanoilne skupine, karboksilne skupine, C1-8 alkilooksikarbonilne skupine, merkapto skupine, nitro skupine, amino skupine, urea skupine, tiourea skupine i amino C1-8 alkilne skupine, (b) hidroksilne skupine, (c) okso skupine, (d) alkanoiloksi skupine, (e) amino skupine, (f) karboksilne skupine, (g) alkoksi skupine i (h) alkilooksikarbonilne skupine.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da R5 predstavlja atom vodika, po supstituiranu C1-8 alkilnu skupin, C2-8 alkenilnu skupinu, C2-8 alkinilnu skupinu, C3-8 cikloalkilnu skupinu ili po izboru supstituiranu C1-8 alkanoilnu skupinu ili R4 i R5 mogu tvoriti zasićeni heterociklički prsten zajedno sa susjednim atomom dušika, pri čemu je supstituent na alkilnoj skupini ili alkanoilnoj skupini najmanje jedan spstituient koji je odabran od (a) arilne skupine, heteroarilne skupine ili arilen skupine koja po izboru može imati, na prstenu, jamanje jedan supstituent koji je odabran od atoma halogena, cijano skupine, C1-8 alkilne skupine, halogeno C1-8 alkilne skupine, C2-8 alkeniln skupine, C2-8 alkinilne skupine, C1-8 alkoksi skupine, C1-8 alkiltio skupine, hidroksilne skupine, okso skupine, skupine formila, C2-8 alkanoilne skupine, karboksilne skupine, C1-8 alkiloksikarbonilne skupine, nitro skupine, amino skupine i amino C1-8 alkilne skupine, (b) hidroksilne skupine, (c) okso skupine i (d) C2-8 alkanoiloksi skupine.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da su R3 i R4 svaki neovisno atom vodika, C1-8 alkilna skupina, hidroksi C1-8 alkilna skupina, di(C1-8 alkil)amino C1-8 alkilna skupina ili amino C2-8 alkanoilna skupina.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da je A ravna ili razgranana alkilenska skupina koja ima 2 do 6 ugljikovih atoma i po izboru ima najmanje jedan supstituent odabran od karboksilne skupine, atoma halogena, cijano skupine, C2-8 alkenilne skupine, C2-8 alkinilne skupine, amino C1-8 alkilne skupine, po izboru supstituirane fenil C1-8 alkilne skupine i po izboru supstituirane heteroaril C1-8 alkilne skupine.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da je A ravna ili razgranana alkilenska skupina koja ima 2 do 6 ugljikova atoma.
8. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da kada je A ravna ili razgranana alkilenska skupina supstituirana skupinom koja je odabrana po izboru od sustituirane aralkilne skupine i po izboru supstituirane heteroarilalkilne skupine, R4 i R5 su vodikov atom ili C1-3 alkilna skupina.
9. Farmaceutski pripravak, naznačen time, da se sastoji od spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 8.
10. Spoj u skladu s patentnim zahtjevima 1 do 8, naznačen time, da je za uporabu u prevenciji i/ili liječenju glaukoma, očne hipertenzije ili srčanožilnih bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010286445 | 2010-12-22 | ||
| PCT/JP2011/079725 WO2012086727A1 (ja) | 2010-12-22 | 2011-12-21 | 新たな置換イソキノリン誘導体 |
| EP11851146.8A EP2657227B1 (en) | 2010-12-22 | 2011-12-21 | Novel substituted isoquinoline derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160465T1 true HRP20160465T1 (hr) | 2016-06-03 |
Family
ID=46313995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160465TT HRP20160465T1 (hr) | 2010-12-22 | 2016-05-03 | Novi supstituirani derivati izokinolina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8883792B2 (hr) |
| EP (1) | EP2657227B1 (hr) |
| JP (1) | JP5781093B2 (hr) |
| KR (1) | KR101911324B1 (hr) |
| CN (1) | CN103270024B (hr) |
| AU (1) | AU2011345969B2 (hr) |
| BR (1) | BR112013015604B1 (hr) |
| CA (1) | CA2822787C (hr) |
| CY (1) | CY1117560T1 (hr) |
| DK (1) | DK2657227T3 (hr) |
| EA (1) | EA022646B1 (hr) |
| ES (1) | ES2571529T3 (hr) |
| HK (1) | HK1185619A1 (hr) |
| HR (1) | HRP20160465T1 (hr) |
| HU (1) | HUE029976T2 (hr) |
| MX (1) | MX2013007296A (hr) |
| NZ (1) | NZ612336A (hr) |
| PL (1) | PL2657227T3 (hr) |
| PT (1) | PT2657227T (hr) |
| TW (1) | TWI527799B (hr) |
| WO (1) | WO2012086727A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021042126A (ja) * | 2017-12-27 | 2021-03-18 | 佐藤製薬株式会社 | アリールオキシ化合物 |
| JP7425482B2 (ja) | 2018-12-17 | 2024-01-31 | 株式会社デ・ウエスタン・セラピテクス研究所 | イソキノリンスルホンアミドの新規な形態 |
| JPWO2020129877A1 (ja) * | 2018-12-18 | 2021-10-28 | 株式会社デ・ウエスタン・セラピテクス研究所 | イソキノリンスルホニルクロリド酸付加塩及びその製造方法 |
| WO2020172615A1 (en) | 2019-02-22 | 2020-08-27 | Glaukos Corporation | Compounds for the treatment of ocular disease |
| CN114340740A (zh) * | 2019-07-01 | 2022-04-12 | 库拉森疗法公司 | β肾上腺素能激动剂及其使用方法 |
| CN110616439B (zh) * | 2019-10-31 | 2020-06-30 | 安阳师范学院 | 电化学氧化合成4-磺酸取代异喹啉酮衍生物的方法 |
| AU2021331624A1 (en) * | 2020-08-31 | 2023-05-04 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985870A (en) | 1995-03-10 | 1999-11-16 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US6169085B1 (en) | 1995-03-10 | 2001-01-02 | G. D. Searle & Company | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US6667307B2 (en) | 1997-12-19 | 2003-12-23 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| AU720326B2 (en) * | 1995-12-21 | 2000-05-25 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| JP2005232175A (ja) | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| US20050272723A1 (en) | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| AU2005289881A1 (en) * | 2004-09-23 | 2006-04-06 | Amgen Inc. | Substituted sulfonamidopropionamides and methods of use |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| AU2009231967B2 (en) | 2008-04-04 | 2013-02-07 | Merck Sharp & Dohme Corp. | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| CA2729186C (en) | 2008-07-08 | 2018-01-16 | Catabasis Pharmaceuticals, Inc. | Fatty acid acetylated salicylates and their uses |
| JP2012525386A (ja) | 2009-05-01 | 2012-10-22 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 疾患の治療のための二重機構阻害剤 |
| AU2010261206B2 (en) | 2009-06-19 | 2015-10-08 | D. Western Therapeutics Institute, Inc. | Substituted isoquinoline derivative |
-
2011
- 2011-12-21 PL PL11851146.8T patent/PL2657227T3/pl unknown
- 2011-12-21 PT PT118511468T patent/PT2657227T/pt unknown
- 2011-12-21 CN CN201180061578.2A patent/CN103270024B/zh active Active
- 2011-12-21 ES ES11851146T patent/ES2571529T3/es active Active
- 2011-12-21 AU AU2011345969A patent/AU2011345969B2/en active Active
- 2011-12-21 KR KR1020137015956A patent/KR101911324B1/ko active IP Right Grant
- 2011-12-21 EA EA201390939A patent/EA022646B1/ru unknown
- 2011-12-21 WO PCT/JP2011/079725 patent/WO2012086727A1/ja active Application Filing
- 2011-12-21 JP JP2012549860A patent/JP5781093B2/ja active Active
- 2011-12-21 HU HUE11851146A patent/HUE029976T2/en unknown
- 2011-12-21 NZ NZ612336A patent/NZ612336A/en unknown
- 2011-12-21 DK DK11851146.8T patent/DK2657227T3/en active
- 2011-12-21 MX MX2013007296A patent/MX2013007296A/es active IP Right Grant
- 2011-12-21 EP EP11851146.8A patent/EP2657227B1/en active Active
- 2011-12-21 BR BR112013015604-0A patent/BR112013015604B1/pt active IP Right Grant
- 2011-12-21 CA CA2822787A patent/CA2822787C/en active Active
- 2011-12-21 US US13/995,300 patent/US8883792B2/en active Active
- 2011-12-22 TW TW100148109A patent/TWI527799B/zh active
-
2013
- 2013-11-26 HK HK13113181.7A patent/HK1185619A1/zh unknown
-
2016
- 2016-05-03 HR HRP20160465TT patent/HRP20160465T1/hr unknown
- 2016-05-27 CY CY20161100465T patent/CY1117560T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2657227T3 (en) | 2016-08-01 |
| CN103270024A (zh) | 2013-08-28 |
| NZ612336A (en) | 2014-05-30 |
| CA2822787A1 (en) | 2012-06-28 |
| PT2657227T (pt) | 2016-08-01 |
| KR20130142163A (ko) | 2013-12-27 |
| MX2013007296A (es) | 2013-08-26 |
| AU2011345969A1 (en) | 2013-07-11 |
| EP2657227B1 (en) | 2016-04-27 |
| AU2011345969B2 (en) | 2016-04-21 |
| EA022646B1 (ru) | 2016-02-29 |
| JP5781093B2 (ja) | 2015-09-16 |
| CA2822787C (en) | 2018-07-17 |
| BR112013015604B1 (pt) | 2021-11-03 |
| EP2657227A1 (en) | 2013-10-30 |
| TW201305112A (zh) | 2013-02-01 |
| JPWO2012086727A1 (ja) | 2014-06-05 |
| CY1117560T1 (el) | 2017-04-26 |
| US8883792B2 (en) | 2014-11-11 |
| TWI527799B (zh) | 2016-04-01 |
| BR112013015604A2 (pt) | 2018-07-24 |
| KR101911324B1 (ko) | 2018-10-25 |
| EP2657227A4 (en) | 2013-11-27 |
| HK1185619A1 (zh) | 2014-02-21 |
| US20130274269A1 (en) | 2013-10-17 |
| EA201390939A1 (ru) | 2013-12-30 |
| PL2657227T3 (pl) | 2016-09-30 |
| WO2012086727A1 (ja) | 2012-06-28 |
| HUE029976T2 (en) | 2017-04-28 |
| CN103270024B (zh) | 2015-07-08 |
| ES2571529T3 (es) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160465T1 (hr) | Novi supstituirani derivati izokinolina | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20161092T1 (hr) | Cdk inhibitori | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| SI3025585T1 (en) | Composition for the control of plant diseases and its use | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| RS54048B1 (en) | PARASITICIDE COMPOUNDS OF DIHYDROISOXAZOLE | |
| MY168201A (en) | Agricultural And Horticultural Fungicidal Composition | |
| BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
| BR112014016328A8 (pt) | novo derivado de nicotinamida ou sal do mesmo | |
| MX2009005449A (es) | Compuesto heteromonociclico y uso del mismo. | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR086121A1 (es) | Derivados de oxazina y una composicion farmaceutica para inhibir bace1 que los contienen | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| MX2014002833A (es) | Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4. | |
| WO2007137874A8 (en) | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | |
| BR112015015275A8 (pt) | composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso | |
| HRP20151419T1 (hr) | Derivati 2-okso-1-imidazolidinil imidazotiadiazola | |
| HRP20192041T1 (hr) | [derivati 7-(morfolinil)-2-(n-piperazinil) metil tieno [2, 3-c]piridina kao lijekovi protiv raka] | |
| AR060904A1 (es) | Derivados de 3,4-dihidro-2h-benzo [1,4] oxazina y tiazina como inhibidores de cetp | |
| AR077367A1 (es) | 2- carboxamida -cicloamino-ureas sustituidas |